Literature DB >> 22923147

Low-titer anti-GAD-antibody-positive cerebellar ataxia.

Kazunori Nanri1, Hisayoshi Niwa, Hiroshi Mitoma, Asako Takei, Junko Ikeda, Toshihide Harada, Mitsunori Okita, Masafumi Takeguchi, Takeshi Taguchi, Hidehiro Mizusawa.   

Abstract

The majority of cases of anti-glutamic acid decarboxylase (GAD)-antibody-positive cerebellar ataxia are reported to have high levels of anti-GAD antibody, and the diagnostic value of low titers of anti-GAD antibody in a patient with cerebellar ataxia is still unknown. The purpose of this study was to verify the characteristics of low-titer-anti-GAD-antibody-positive cerebellar ataxia patients and the diagnostic value of low titers of anti-GAD antibody in patients with cerebellar ataxia. The subjects were six patients positive for low-titer GAD antibody (<100 U/mL). We examined them with MRI, including voxel-based morphometry, and with single-photon emission computed tomography and monitored the GAD antibody index in the cerebrospinal fluid. The levels of antineuronal, antigliadin, anti-SS-A, antithyroid antibodies, and of vitamins E, B1, and B12 were determined. Thoracic and abdominal CT scans were performed to exclude a paraneoplastic origin. We treated three patients with immunotherapy. All cases showed cortical cerebellar atrophy. The GAD antibody index in three of the five patients reviewed was >1.0. Two of the six patients were thyroid antibody-positive, and one was both antinuclear- and anti-SS-A antibody-positive. After the administration of immunotherapy to three patients, two showed clear effectiveness, and one, transient effectiveness. Effectiveness was greatest in the two patients with familial occurrence of the disease. In cerebellar ataxia, regardless of family history or isolated illness, it is critical to measure the GAD antibody level, and, even with a low titer level, if the result is positive, immunotherapy should be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22923147     DOI: 10.1007/s12311-012-0411-5

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  15 in total

1.  [A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative].

Authors:  B Birand; P Cabre; M Bonnan; S Olindo; D Smadja
Journal:  Rev Med Interne       Date:  2006-06-05       Impact factor: 0.728

2.  Brain imaging in cerebellar ataxia associated with autoimmune polyglandular syndrome type 2.

Authors:  Mario Manto; P Jissendi
Journal:  J Neuroimaging       Date:  2010-11-17       Impact factor: 2.486

3.  Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment.

Authors:  V Nociti; G Frisullo; T Tartaglione; A K Patanella; R Iorio; P A Tonali; A P Batocchi
Journal:  Eur J Neurol       Date:  2009-10-28       Impact factor: 6.089

4.  Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies.

Authors:  M C Dalakas; M Li; M Fujii; D M Jacobowitz
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

5.  The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.

Authors:  Marinos C Dalakas
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

6.  Prevalence of ICA and GAD antibodies at initial presentation of type 1 diabetes mellitus in Singapore children.

Authors:  Y S Lee; W Y Ng; A C Thai; K F Lui; K Y Loke
Journal:  J Pediatr Endocrinol Metab       Date:  2001-06       Impact factor: 1.634

7.  Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.

Authors:  J Honnorat; A Saiz; B Giometto; A Vincent; L Brieva; C de Andres; J Maestre; N Fabien; A Vighetto; R Casamitjana; C Thivolet; B Tavolato; J Antoine; P Trouillas; F Graus
Journal:  Arch Neurol       Date:  2001-02

8.  Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia.

Authors:  Kazunori Nanri; Mitsunori Okita; Masafumi Takeguchi; Takeshi Taguchi; Tomoko Ishiko; Hirohiko Saito; Takao Otsuka; Hiroshi Mitoma; Kiyoshi Koizumi
Journal:  Intern Med       Date:  2009-05-15       Impact factor: 1.271

9.  Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases.

Authors:  Mario-Ubaldo Manto; Marie-Aline Laute; Michèle Aguera; Véronique Rogemond; Massimo Pandolfo; Jérome Honnorat
Journal:  Ann Neurol       Date:  2007-06       Impact factor: 10.422

10.  Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia.

Authors:  Mario U Manto; Christiane S Hampe; Véronique Rogemond; Jérome Honnorat
Journal:  Orphanet J Rare Dis       Date:  2011-02-04       Impact factor: 4.123

View more
  15 in total

1.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

2.  Anti-GAD Antibody, Seizures, Cerebellar Ataxias and Vitiligo: A Diagnostic Challenge.

Authors:  Hazael Flores-Cantu; Carlos R Camara-Lemarroy; Hector J Calderon-Hernandez; Maria A Zapata-Rivera; Jesus Z Villareal-Perez; Hector J Villareal-Velazquez
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

3.  Gravity-Independent Upbeat Nystagmus in Syndrome of Anti-GAD Antibodies.

Authors:  Daniel Feldman; Jorge Otero-Millan; Aasef G Shaikh
Journal:  Cerebellum       Date:  2019-04       Impact factor: 3.847

4.  Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.

Authors:  Timotej Petrijan; Marija Menih
Journal:  Cerebellum       Date:  2017-08       Impact factor: 3.847

Review 5.  Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.

Authors:  José Fidel Baizabal-Carvallo; Marlene Alonso-Juarez
Journal:  J Neural Transm (Vienna)       Date:  2017-07-08       Impact factor: 3.575

Review 6.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

7.  Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.

Authors:  Vincent Planche; Ana Marques; Miguel Ulla; Marc Ruivard; Franck Durif
Journal:  Cerebellum       Date:  2014-06       Impact factor: 3.847

Review 8.  GAD antibodies in neurological disorders - insights and challenges.

Authors:  Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2020-05-26       Impact factor: 42.937

Review 9.  Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias.

Authors:  Hiroshi Mitoma; Keya Adhikari; Daniel Aeschlimann; Partha Chattopadhyay; Marios Hadjivassiliou; Christiane S Hampe; Jérôme Honnorat; Bastien Joubert; Shinji Kakei; Jongho Lee; Mario Manto; Akiko Matsunaga; Hidehiro Mizusawa; Kazunori Nanri; Priya Shanmugarajah; Makoto Yoneda; Nobuhiro Yuki
Journal:  Cerebellum       Date:  2016-04       Impact factor: 3.847

10.  Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats.

Authors:  Christiane S Hampe; Laura Petrosini; Paola De Bartolo; Paola Caporali; Debora Cutuli; Daniela Laricchiuta; Francesca Foti; Jared R Radtke; Veronika Vidova; Jérôme Honnorat; Mario Manto
Journal:  Orphanet J Rare Dis       Date:  2013-06-05       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.